Infinity partners with Mundipharma, Purdue

Infinity (NASDAQ:INFI) partnered with Purdue (Stamford, Conn.) and Purdue affiliate Mundipharma (Cambridge, U.K.) to co-develop and commercialize Infinity's early clinical and discovery programs in a pair of deals. One deal is with Mundipharma for cancer and includes Infinity's IPI-926, a Hedgehog pathway inhibitor in Phase I testing in solid tumors. The second deal, which is with both Mundipharma and Purdue, includes an option to Infinity's fatty acid amide hydrolase (FAAH) program for neuropathic pain upon completion of Phase I trials. ...